Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,959 | -10,064 | -6,280 | -2,810 | -14,287 |
| Depreciation Amortization | 22 | 17 | 12 | 6 | 7 |
| Accounts payable and accrued liabilities | -314 | -516 | -704 | -350 | 828 |
| Other Working Capital | -1,055 | -347 | -1,473 | -1,162 | 1,619 |
| Other Operating Activity | 749 | 864 | 867 | 380 | -344 |
| Operating Cash Flow | $-13,557 | $-10,046 | $-7,578 | $-3,936 | $-12,178 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -16 | -16 | -8 | -93 |
| Investing Cash Flow | $-16 | $-16 | $-16 | $-8 | $-93 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 16,140 | 16,000 | 16,000 | N/A | 5,789 |
| Other Financing Activity | -1,319 | -1,312 | -1,311 | 14,710 | -649 |
| Financing Cash Flow | $14,822 | $14,688 | $14,689 | $14,710 | $5,140 |
| Exchange Rate Effect | -7 | 17 | -7 | -2 | -8 |
| Beginning Cash Position | 21,648 | 21,648 | 21,648 | 21,648 | 28,787 |
| End Cash Position | 22,890 | 26,291 | 28,736 | 32,411 | 21,648 |
| Net Cash Flow | $1,250 | $4,644 | $7,088 | $10,763 | $-7,139 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,557 | -10,046 | -7,578 | -3,936 | -12,178 |
| Capital Expenditure | -16 | -16 | -16 | -8 | -93 |
| Free Cash Flow | -13,572 | -10,061 | -7,593 | -3,944 | -12,271 |